Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers...
Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA
Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial ( Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Jun 2019
Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 m...
Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA
Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Guiding treatment decisions through the use of molecular profiling in breast can...
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Guiding treatment decisions through the use of molecular profiling in breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Managing metastatic breast cancer and beyond using PARP inhibitors
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Updates in metastatic and early-stage breast cancer
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
PARP inhibitors in metastatic breast cancer: Where are we now?
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019
ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus riboc...
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor ...
Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies ( Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands )
10 Jun 2019
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0...
Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )
10 Jun 2019
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemo...
Prof Thomas Flaig - University of Colorado Denver, Denver, USA
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )
10 Jun 2019
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC...
Prof Hope Rugo - University of California, San Francisco, USA
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )
10 Jun 2019
Updates in the management of pancreatic cancer from ASCO 2019
Dr Ian Chau, Prof Michel Ducreux and Dr Vaihab Sahai
Updates in the management of pancreatic cancer from ASCO 2019 ( Dr Ian Chau, Prof Michel Ducreux and Dr Vaihab Sahai )
7 Jun 2019